CS-8958 Phase 3 study - A randomized, single-blind, placebo-controlled study of nebulized CS-8958 in the treatment of influenza virus infection -

Trial Profile

CS-8958 Phase 3 study - A randomized, single-blind, placebo-controlled study of nebulized CS-8958 in the treatment of influenza virus infection -

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Laninamivir (Primary)
  • Indications Influenza virus infections
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 13 Sep 2017 Status changed from not yet recruiting to completed.
    • 10 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top